NO985484L - FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi - Google Patents

FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi

Info

Publication number
NO985484L
NO985484L NO985484A NO985484A NO985484L NO 985484 L NO985484 L NO 985484L NO 985484 A NO985484 A NO 985484A NO 985484 A NO985484 A NO 985484A NO 985484 L NO985484 L NO 985484L
Authority
NO
Norway
Prior art keywords
hyperuricemia
prevention
preparation
treatment
Prior art date
Application number
NO985484A
Other languages
English (en)
Other versions
NO985484D0 (no
Inventor
Toshihiko Fujiwara
Koichi Iwasaki
Hiroyoshi Horikoshi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO985484D0 publication Critical patent/NO985484D0/no
Publication of NO985484L publication Critical patent/NO985484L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
NO985484A 1997-11-25 1998-11-24 FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi NO985484L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32318297 1997-11-25

Publications (2)

Publication Number Publication Date
NO985484D0 NO985484D0 (no) 1998-11-24
NO985484L true NO985484L (no) 1999-05-26

Family

ID=18151987

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985484A NO985484L (no) 1997-11-25 1998-11-24 FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi

Country Status (23)

Country Link
US (1) US6353009B1 (no)
EP (1) EP0919232B1 (no)
KR (1) KR19990045531A (no)
AR (1) AR011231A1 (no)
AT (1) ATE278400T1 (no)
AU (1) AU744653B2 (no)
BR (1) BR9805012A (no)
CA (1) CA2254394C (no)
CZ (1) CZ378898A3 (no)
DE (2) DE69826811T4 (no)
ES (1) ES2230657T3 (no)
HK (1) HK1020259A1 (no)
HU (2) HUP9902721A2 (no)
ID (1) ID21332A (no)
IL (1) IL127219A (no)
NO (1) NO985484L (no)
NZ (1) NZ332895A (no)
PL (1) PL329893A1 (no)
RU (1) RU2190425C2 (no)
SA (1) SA99191266A (no)
TR (1) TR199802441A3 (no)
TW (1) TW592697B (no)
ZA (1) ZA9810788B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
US6794154B1 (en) * 1999-05-27 2004-09-21 Tanabe Seiyaku Co., Ltd. Remedies for kidney diseases and method for screening the same
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
EP2324830A1 (en) * 2002-03-05 2011-05-25 TransTech Pharma Inc. Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
JP2005092923A (ja) * 2003-09-12 2005-04-07 Renesas Technology Corp 半導体記憶装置
EP1778261A4 (en) 2004-07-21 2010-08-11 Univ Florida COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE
CA2617161A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
WO2008126732A1 (ja) * 2007-04-05 2008-10-23 Daiichi Sankyo Company, Limited 縮合二環式ヘテロアリール誘導体
ES2617191T3 (es) 2009-03-05 2017-06-15 Daiichi Sankyo Company, Limited Derivado de piridina como inhibidor de PPARY
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
BR112014017902A2 (pt) * 2012-01-27 2017-08-22 Teijin Pharma Limited E National Univ Corporation Tottori Univ Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
ES2762860T3 (es) 2013-05-22 2020-05-26 Telomere Diagnostics Inc Medidas de abundancia de telómeros cortos
US20190152967A1 (en) * 2016-04-04 2019-05-23 The Schepens Eye Research Institute, Inc. Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
ZA873745B (en) 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
DE10199003I1 (de) 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5120754A (en) 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US4897405A (en) 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469383A (ja) 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
EP0648242B1 (en) * 1992-07-02 1997-05-02 Novo Nordisk A/S POLYMERIZATION OF LIGNIN AT ALKALINE pH
GB9223059D0 (en) 1992-11-04 1992-12-16 Bamford Excavators Ltd Intercooler apparatus
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JPH06211657A (ja) 1993-01-21 1994-08-02 Mochida Pharmaceut Co Ltd 尿酸排泄剤
CZ283339B6 (cs) 1993-09-15 1998-03-18 Sankyo Company Limited Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu
CA2157032C (en) * 1993-12-27 1999-09-28 Hisashi Shinkai Isoxazolidinedione derivative and use thereof
RU2151145C1 (ru) 1994-04-11 2000-06-20 Санкио Компани Лимитед Промежуточное соединение для получения гетероциклических соединений, обладающих антидиабетической активностью
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Also Published As

Publication number Publication date
CA2254394C (en) 2009-11-17
BR9805012A (pt) 2000-03-21
HUP9902721A2 (hu) 1999-12-28
DE69826811T2 (de) 2005-06-16
SA99191266A (ar) 2005-12-03
HUP9802721A1 (hu) 2000-03-28
TW592697B (en) 2004-06-21
AU744653B2 (en) 2002-02-28
DE69826811D1 (de) 2004-11-11
RU2190425C2 (ru) 2002-10-10
ZA9810788B (en) 1999-05-25
PL329893A1 (en) 1999-06-07
CA2254394A1 (en) 1999-05-25
DE69826811T4 (de) 2006-09-21
NO985484D0 (no) 1998-11-24
AU9410298A (en) 1999-06-17
US6353009B1 (en) 2002-03-05
TR199802441A2 (xx) 1999-10-21
EP0919232B1 (en) 2004-10-06
KR19990045531A (ko) 1999-06-25
ID21332A (id) 1999-05-27
IL127219A0 (en) 1999-09-22
HU9802721D0 (en) 1999-01-28
IL127219A (en) 2001-08-08
CZ378898A3 (cs) 1999-07-14
ATE278400T1 (de) 2004-10-15
EP0919232A1 (en) 1999-06-02
NZ332895A (en) 2001-04-27
HK1020259A1 (en) 2000-04-07
TR199802441A3 (tr) 1999-10-21
AR011231A1 (es) 2000-08-02
ES2230657T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
NO985484L (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
NO20014046D0 (no) Gabapentinderivater for forhindring og behandling av visceral smerte
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
DK1041879T4 (da) Desinfektionsmiddel og fremstillingsmetode
NO961006D0 (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO983641D0 (no) Fremgangsmåte til behandling og farmasöytisk preparat
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20003070D0 (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
FI980246A (fi) Menetelmä keittimen käyttämiseksi ja keitin
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
NO983512D0 (no) Midler for behandling og forhindring av AIDS
NO972426D0 (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
NO20000706D0 (no) Metode for økning av biotilgjengeligheten av feksofenadin og dens derivater
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO20020369D0 (no) Preparat for forebyggelse og behandling av nyredysfunksjon og -sykdommer
NO20012099D0 (no) Fremgangsmåte for fremstilling av 4-arylpiperidin-3- carbinoler og beslektede forbindelser
NO20022990L (no) Fremgangsmåte og sammensetning for behandling av smerte
NO990018D0 (no) Belegg og fremgangsmÕte for fremstilling derav
NO20022984D0 (no) Forbindelse og fremgangsmåte for behandling av smerte
NO990185L (no) FremgangsmÕte for fremstilling av naftypyridoner og mellomprodukter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application